Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?

Joop E. Arends; Faydra I. Lieveld; Lauke L. Boeijen; Clara T M M De Kanter; Karel J. van Erpecum; Dominique Salmon; Andy I M Hoepelman; Tarik Asselah; Andrew Ustianowski

doi:10.1016/j.jhep.2015.06.034

Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?

Joop E. Arends^*, Faydra I. Lieveld, Lauke L. Boeijen, Clara T M M De Kanter, Karel J. van Erpecum, Dominique Salmon, Andy I M Hoepelman, Tarik Asselah, Andrew Ustianowski

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Evidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted drug resistance.

Original language	English
Pages (from-to)	1254-1262
Number of pages	9
Journal	Journal of Hepatology
Volume	63
Issue number	5
DOIs	https://doi.org/10.1016/j.jhep.2015.06.034
Publication status	Published - 1 Nov 2015

Keywords

Direct-acting antiviral agents
Hepatitis C
HIV
Liver fibrosis
Pegylated interferon

Access to Document

10.1016/j.jhep.2015.06.034

Cite this

@article{a204e57661c144d8a34f67ee8f5af763,

title = "Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?",

abstract = "Evidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted drug resistance.",

keywords = "Direct-acting antiviral agents, Hepatitis C, HIV, Liver fibrosis, Pegylated interferon",

author = "Arends, {Joop E.} and Lieveld, {Faydra I.} and Boeijen, {Lauke L.} and {De Kanter}, {Clara T M M} and {van Erpecum}, {Karel J.} and Dominique Salmon and Hoepelman, {Andy I M} and Tarik Asselah and Andrew Ustianowski",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.jhep.2015.06.034",

language = "English",

volume = "63",

pages = "1254--1262",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Natural history and treatment of HCV/HIV coinfection

T2 - Is it time to change paradigms?

AU - Arends, Joop E.

AU - Lieveld, Faydra I.

AU - Boeijen, Lauke L.

AU - De Kanter, Clara T M M

AU - van Erpecum, Karel J.

AU - Salmon, Dominique

AU - Hoepelman, Andy I M

AU - Asselah, Tarik

AU - Ustianowski, Andrew

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Evidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted drug resistance.

AB - Evidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted drug resistance.

KW - Direct-acting antiviral agents

KW - Hepatitis C

KW - HIV

KW - Liver fibrosis

KW - Pegylated interferon

UR - http://www.scopus.com/inward/record.url?scp=84945458494&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2015.06.034

DO - 10.1016/j.jhep.2015.06.034

M3 - Article

C2 - 26186987

AN - SCOPUS:84940056458

SN - 0168-8278

VL - 63

SP - 1254

EP - 1262

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 5

ER -

Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this